BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24294969)

  • 1. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
    Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
    J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.
    Bregman H; Chakka N; Guzman-Perez A; Gunaydin H; Gu Y; Huang X; Berry V; Liu J; Teffera Y; Huang L; Egge B; Mullady EL; Schneider S; Andrews PS; Mishra A; Newcomb J; Serafino R; Strathdee CA; Turci SM; Wilson C; DiMauro EF
    J Med Chem; 2013 Jun; 56(11):4320-42. PubMed ID: 23701517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor.
    Shultz MD; Cheung AK; Kirby CA; Firestone B; Fan J; Chen CH; Chen Z; Chin DN; Dipietro L; Fazal A; Feng Y; Fortin PD; Gould T; Lagu B; Lei H; Lenoir F; Majumdar D; Ochala E; Palermo MG; Pham L; Pu M; Smith T; Stams T; Tomlinson RC; Touré BB; Visser M; Wang RM; Waters NJ; Shao W
    J Med Chem; 2013 Aug; 56(16):6495-511. PubMed ID: 23844574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.
    Buchstaller HP; Anlauf U; Dorsch D; Kuhn D; Lehmann M; Leuthner B; Musil D; Radtki D; Ritzert C; Rohdich F; Schneider R; Esdar C
    J Med Chem; 2019 Sep; 62(17):7897-7909. PubMed ID: 31381853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.
    Bregman H; Gunaydin H; Gu Y; Schneider S; Wilson C; DiMauro EF; Huang X
    J Med Chem; 2013 Feb; 56(3):1341-5. PubMed ID: 23316926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights of tankyrases: A novel target for drug discovery.
    Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
    Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular insights on TNKS1/TNKS2 and inhibitor-IWR1 interactions.
    Kirubakaran P; Kothandan G; Cho SJ; Muthusamy K
    Mol Biosyst; 2014 Feb; 10(2):281-93. PubMed ID: 24291818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
    Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
    Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
    Shirai F; Mizutani A; Yashiroda Y; Tsumura T; Kano Y; Muramatsu Y; Chikada T; Yuki H; Niwa H; Sato S; Washizuka K; Koda Y; Mazaki Y; Jang MK; Yoshida H; Nagamori A; Okue M; Watanabe T; Kitamura K; Shitara E; Honma T; Umehara T; Shirouzu M; Fukami T; Seimiya H; Yoshida M; Koyama H
    J Med Chem; 2020 Apr; 63(8):4183-4204. PubMed ID: 32202790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
    Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
    Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity.
    Narwal M; Koivunen J; Haikarainen T; Obaji E; Legala OE; Venkannagari H; Joensuu P; Pihlajaniemi T; Lehtiö L
    J Med Chem; 2013 Oct; 56(20):7880-9. PubMed ID: 24116873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
    Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
    PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
    Shirai F; Tsumura T; Yashiroda Y; Yuki H; Niwa H; Sato S; Chikada T; Koda Y; Washizuka K; Yoshimoto N; Abe M; Onuki T; Mazaki Y; Hirama C; Fukami T; Watanabe H; Honma T; Umehara T; Shirouzu M; Okue M; Kano Y; Watanabe T; Kitamura K; Shitara E; Muramatsu Y; Yoshida H; Mizutani A; Seimiya H; Yoshida M; Koyama H
    J Med Chem; 2019 Apr; 62(7):3407-3427. PubMed ID: 30883102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
    Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
    Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tankyrase 1 Inhibitors with Drug-like Properties Identified by Screening a DNA-Encoded Chemical Library.
    Samain F; Ekblad T; Mikutis G; Zhong N; Zimmermann M; Nauer A; Bajic D; Decurtins W; Scheuermann J; Brown PJ; Hall J; Gräslund S; Schüler H; Neri D; Franzini RM
    J Med Chem; 2015 Jun; 58(12):5143-9. PubMed ID: 26061013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel binding mode of a potent and selective tankyrase inhibitor.
    Gunaydin H; Gu Y; Huang X
    PLoS One; 2012; 7(3):e33740. PubMed ID: 22438990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tankyrases as drug targets.
    Lehtiö L; Chi NW; Krauss S
    FEBS J; 2013 Aug; 280(15):3576-93. PubMed ID: 23648170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors.
    Haikarainen T; Koivunen J; Narwal M; Venkannagari H; Obaji E; Joensuu P; Pihlajaniemi T; Lehtiö L
    ChemMedChem; 2013 Dec; 8(12):1978-85. PubMed ID: 24130191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
    Waaler J; Machon O; Tumova L; Dinh H; Korinek V; Wilson SR; Paulsen JE; Pedersen NM; Eide TJ; Machonova O; Gradl D; Voronkov A; von Kries JP; Krauss S
    Cancer Res; 2012 Jun; 72(11):2822-32. PubMed ID: 22440753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.